The ICRS Newsletter Autumn 2022 Issue is now out of press. Hard copies will be delivered to our members and partners worldwide in the next 3 weeks. Enjoy Reading…
The ICRS Newsletter Autumn 2022 Issue is now out of press. Hard copies will be delivered to our members and partners worldwide in the next 3 weeks. Enjoy Reading…
Procedure is part of global clinical trial for technology developed by Israel’s CartiHeal, which hopes to bring relief to millions of sufferers of knee pain
Vericel (Nasdaq: VCEL), a specialty biologics company with three approved cellular therapy products on the market might still be underappreciated by investors after its recent run?
OR AKIVA, Israel and PRINCETON, New Jersey, August 28, 2017 /PRNewswire/ — Regentis Biomaterials Ltd., a privately held company developing proprietary hydrogels for tissue regeneration, announced today it has received European CE mark approval for its GelrinC® biodegradable implant.
TELTOW, BERLIN, GERMANY / ACCESSWIRE / July 12, 2017 / Today, CO.DON AG received the Commission’s implementing decision of 10.07.2017 on the granting of marketing authorization for the human pharmaceutical product,
European Union (EU) regulators yesterday recommended approval of a third-generation transplant product of autologous cultured cartilage cells for repairing worn-out knees that doesn’t require any scaffold material.